STAT+: Genentech is soliciting research that can be used to blunt pharma reforms in Washington

Summary: Genentech, a large pharmaceutical company, is offering researchers and academics up to $125,000 in grant money to write new papers. The catch? The topics they want researched sound exactly like the talking points the company uses to fight against new drug pricing laws in Washington.

The company is asking for "independent" research on how changing drug prices might hurt future medical inventions, and why drug research is a strategic national asset. They want these papers submitted by June 30. Basically, the company wants academics to help them argue that making medicines cheaper right now could make it harder to discover new, life-saving drugs in the future.

For more details, see statnews-2 at statnews.com/pharmalot/2026/05/22/genentech-soliciting-academics-write-papers-to-blunt-pharma-reforms-dc/?utm_campaign=rss (opens in new tab)